Digital therapeutics: evidence-based software as a new class of treatment

A new class of treatment is taking shape. Digital therapeutics (DTx) deliver evidence-based interventions — for insomnia, chronic disease support, rehabilitation and more — through software, often prescribed and clinically supervised. The field’s central promise is scalability: once an intervention is validated, it can reach patients wherever they are, complementing conventional care rather than competing with it.

The challenge: proving and sustaining value

Like any therapy, digital therapeutics succeed on evidence and access. A 2025 analysis in npj Digital Medicine of policy and reimbursement strategies for prescription digital therapeutics highlights how thoughtful benefit design and evaluation pathways can expand patient access to clinically rigorous software treatments.^[1] The practical challenges for the field are familiar to anyone in translational medicine:

• Clinical evidence. Well-designed trials and real-world follow-up demonstrate that a digital intervention genuinely improves outcomes.
• Engagement. A therapy only works if patients use it; human-centred design and clinical integration drive adherence.
• Evaluation frameworks. Health systems benefit from clear, consistent ways to assess digital interventions — an area developing rapidly across countries.
• Lifecycle quality. As software, DTx products evolve continuously and deserve the same disciplined change control as any medical software.

The way forward

The maturing of DTx is a story of convergence: clinical science, software craft, health economics and regulatory competence meeting in one product. Organisations that assemble those skills — and professionals who span more than one of them — are defining the field’s standards as they build it.

A young class with a real evidence culture

Digital therapeutics emerged in the mid-2010s, when the first software products cleared regulatory review on the strength of randomised clinical trials — notably in addiction care and insomnia — establishing the defining principle of the class: software claiming therapeutic effect must prove it the way medicines do. That principle separates DTx from the vast sea of wellness apps. A meditation app can be helpful without a trial; a prescription digital therapeutic for a diagnosed condition earns its status through controlled evidence of clinical benefit.

Health systems then began building the second half of the infrastructure: pathways to pay for evidence-based software. Germany’s DiGA framework, launched in 2020, became the most-watched model — a defined route by which digital health applications demonstrating benefit can be prescribed by physicians and reimbursed by statutory insurers, with conditional listing that allows evidence to mature under real-world conditions. Other European countries have been developing their own assessment routes, each wrestling with the same questions of evidence standards, pricing and integration.

What separates durable products from pilots

• Clinical champions and clear pathways. A DTx succeeds when clinicians know exactly which patient, at which point in the pathway, should receive it — and what to do with the data it returns.
• Engagement engineering. The dose–response of software is adherence; products that sustain use through good design deliver outcomes, and outcomes sustain reimbursement.
• Evidence that keeps growing. The strongest developers treat launch as the start of evidence generation, accumulating real-world outcomes that strengthen both the clinical and the economic case.
• Integration over isolation. Prescribing, onboarding and monitoring woven into existing clinical systems — a therapeutic that lives outside the workflow quietly disappears from it.

Looking ahead

The next chapter will be shaped by convergence: DTx combined with medicines in structured care programmes, health-economic evidence deciding which products scale, and clinicians increasingly expected to evaluate software the way they evaluate any therapy — by asking for the trial, the population, the effect size and the price of the outcome. That evaluative skill set, spanning clinical evidence and health economics, is precisely where professional education in digital health now concentrates.

Where EUSTM fits

The EUSTM Academy’s Professional Certification in Digital Health & Therapeutics (PCDH) addresses digital interventions in clinical context, while the Professional Certification in Health Economics & Outcomes Research (PCHEOR) builds the value-evidence skills that bring digital treatments to patients at scale.

Disclaimer. This Expert Insight is provided by EUSTM for general informational and educational purposes only. It does not constitute medical, clinical, legal, regulatory or other professional advice, and it should not be relied upon as the basis for clinical, regulatory or business decisions. While care is taken in preparing this content, EUSTM makes no representation or warranty as to the accuracy, completeness or currency of any scientific, medical or other statements, and accepts no liability arising from the use of this content. Readers should consult the cited sources, the current official guidance of the relevant authorities and frameworks, and appropriately qualified professionals in their own jurisdiction. References to third-party organisations, publications or frameworks are for information only and do not imply affiliation or endorsement.

← All Expert Insights